68,349 Shares in 4D Molecular Therapeutics, Inc. $FDMT Acquired by Man Group plc

Man Group plc bought a new stake in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) during the second quarter, Holdings Channel.com reports. The fund bought 68,349 shares of the company’s stock, valued at approximately $909,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of FDMT. Jupiter Topco LLC bought a new position in shares of 4D Molecular Therapeutics in the 2nd quarter worth $76,466,000. RA Capital Management L.P. increased its stake in 4D Molecular Therapeutics by 23.9% in the fourth quarter. RA Capital Management L.P. now owns 5,653,211 shares of the company’s stock valued at $42,399,000 after acquiring an additional 1,090,000 shares during the last quarter. Janus Henderson Group PLC raised its position in 4D Molecular Therapeutics by 13.2% during the first quarter. Janus Henderson Group PLC now owns 5,247,151 shares of the company’s stock valued at $48,868,000 after purchasing an additional 611,276 shares in the last quarter. BlackRock Inc. purchased a new stake in 4D Molecular Therapeutics during the second quarter valued at about $60,463,000. Finally, Goldman Sachs Group Inc. raised its position in 4D Molecular Therapeutics by 4.2% during the fourth quarter. Goldman Sachs Group Inc. now owns 4,302,905 shares of the company’s stock valued at $32,272,000 after purchasing an additional 174,489 shares in the last quarter. Hedge funds and other institutional investors own 99.27% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the company. B. Riley Financial reiterated a “buy” rating on shares of 4D Molecular Therapeutics in a report on Monday, August 17th. HC Wainwright reissued a “buy” rating and set a $36.00 price objective on shares of 4D Molecular Therapeutics in a report on Monday, July 20th. The Goldman Sachs Group restated a “buy” rating and issued a $32.00 target price on shares of 4D Molecular Therapeutics in a research report on Thursday, August 13th. Chardan Capital raised 4D Molecular Therapeutics to a “strong-buy” rating in a research note on Tuesday, July 28th. Finally, Wall Street Zen downgraded shares of 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $29.62.

4D Molecular Therapeutics Stock Performance

NASDAQ FDMT opened at $14.70 on Friday. The company has a 50-day simple moving average of $12.47 and a two-hundred day simple moving average of $10.49. 4D Molecular Therapeutics, Inc. has a 12-month low of $6.09 and a 12-month high of $16.93. The firm has a market cap of $812.03 million, a price-to-earnings ratio of -5.59 and a beta of 2.74. The company has a quick ratio of 8.03, a current ratio of 8.03 and a debt-to-equity ratio of 0.05.

4D Molecular Therapeutics (NASDAQ:FDMT) last released its quarterly earnings data on Thursday, August 13th. The company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($1.02) by ($0.02). 4D Molecular Therapeutics had a negative return on equity of 41.33% and a negative net margin of 194.74%.The company had revenue of $3.78 million during the quarter, compared to analysts’ expectations of $3.62 million. On average, equities analysts forecast that 4D Molecular Therapeutics, Inc. will post -4.09 EPS for the current year.

Insider Activity at 4D Molecular Therapeutics

In other 4D Molecular Therapeutics news, insider Scott Bizily sold 9,810 shares of 4D Molecular Therapeutics stock in a transaction that occurred on Tuesday, June 23rd. The stock was sold at an average price of $12.00, for a total value of $117,720.00. Following the transaction, the insider directly owned 8,617 shares of the company’s stock, valued at $103,404. The trade was a 53.24% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider David Kirn sold 114,746 shares of 4D Molecular Therapeutics stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $10.47, for a total value of $1,201,390.62. Following the completion of the transaction, the insider directly owned 942,485 shares in the company, valued at $9,867,817.95. This trade represents a 10.85% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 199,158 shares of company stock worth $2,229,161. 7.90% of the stock is owned by corporate insiders.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.